Pharmacokinetics and biologic activity of the novel mast cell inhibitor, 4-(3-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline in mice.
- 1 January 1999
- journal article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 16 (1) , 117-122
- https://doi.org/10.1023/a:1018835232027
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Inhibition of human glioblastoma cell adhesion and invasion by 4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) and 4-(3'-bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P154).1998
- 4-(3'-Bromo-4'hydroxylphenyl)-amino-6,7-dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells.1998
- Systemic anaphylaxis in the mouse can be mediated largely through IgG1 and Fc gammaRIII. Assessment of the cardiopulmonary changes, mast cell degranulation, and death associated with active or IgE- or IgG1-dependent passive anaphylaxis.Journal of Clinical Investigation, 1997
- Drug-protein binding studies new trends in analytical and experimental methodologyJournal of Chromatography B: Biomedical Sciences and Applications, 1996
- Protein tyrosine phosphorylation as a mechanism of signalling in mast cells and basophilsCellular Signalling, 1995
- Active anaphylaxis in IgE-deficient miceNature, 1994
- Physiological Parameters in Laboratory Animals and HumansPharmaceutical Research, 1993
- Cytokine production by mast cells and basophilsCurrent Opinion in Immunology, 1991
- Augmentation of reverse arthus reaction by mast cells in mice.Journal of Clinical Investigation, 1991
- VASOACTIVE AMINES IN ACUTE INFLAMMATIONAnnals of the New York Academy of Sciences, 1964